UCH-L1 and UCH-L3 regulate the cancer stem cell-like properties through PI3 K/Akt signaling pathway in prostate cancer cells

References

• An Y, Ongkeko WM. 2009. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 5(12):1529–1542.
   PubMed Web of Science ®Google Scholar
• Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. 2006. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 66(11):5723–5728.
   PubMed Web of Science ®Google Scholar
• Bi HL, Zhang XL, Zhang YL, Xie X, Xia YL, Du J, Li HH. 2020. The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor. Sci Adv. 6(16):eaax4826.
   PubMed Web of Science ®Google Scholar
• Cai Z, He S, Li T, Zhao L, Zhang K. 2020. Plumbagin inhibits proliferation and promotes apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inactivating PI3 K/Akt/mTOR pathway. Anim Cells Syst (Seoul). 24(4):197–204.
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA. 2009. The role of PTEN/Akt/PI3 K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 106(1):268–273.
   PubMed Web of Science ®Google Scholar
• Freberg CT, Dahl JA, Timoskainen S, Collas P. 2007. Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell. 18(5):1543–1553.
   PubMed Web of Science ®Google Scholar
• Gu YY, Yang M, Zhao M, Luo Q, Yang L, Peng H, Wang J, Huang SK, Zheng ZX, Yuan XH, et al. 2015. The de-ubiquitinase UCHL1 promotes gastric cancer metastasis via the Akt and Erk1/2 pathways. Tumour Biol. 36(11):8379–8387.
   PubMedGoogle Scholar
• Hussain S, Foreman O, Perkins SL, Witzig TE, Miles RR, van Deursen J, Galardy PJ. 2010. The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia. 24(9):1641–1655.
   PubMed Web of Science ®Google Scholar
• Jang MJ, Baek SH, Kim JH. 2011. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett. 302(2):128–135.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ, Lee KJ. 2009. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 28(1):117–127.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park KC, Chung SS, Bang O, Chung CH. 2003. Deubiquitinating enzymes as cellular regulators. J Biochem. 134(1):9–18.
   PubMed Web of Science ®Google Scholar
• Kimura T, Egawa S. 2018. Epidemiology of prostate cancer in asian countries. Int J Urol. 25(6):524–531.
   PubMed Web of Science ®Google Scholar
• Le H, Zeng F, Xu L, Liu X, Huang Y. 2013. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Mol Med Rep. 8(5):1511–1518.
   PubMed Web of Science ®Google Scholar
• Liu S, Gonzalez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le Devedec SE, et al. 2020. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFbeta-induced breast cancer metastasis. Clin Cancer Res. 26(6):1460–1473.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Nakayama S, Torikoshi Y, Tanaka S, Ishihara H, Taguchi T, Tamaki Y, Noguchi S. 2006. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci. 97(6):523–529.
   PubMed Web of Science ®Google Scholar
• Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J, Li Y. 2014. Cancer stem cells in prostate cancer chemoresistance. Curr Cancer Drug Targets. 14(3):225–240.
   PubMed Web of Science ®Google Scholar
• Ojo D, Lin X, Wong N, Gu Y, Tang D. 2015. Prostate cancer stem-like cells contribute to the development of castration-resistant prostate cancer. Cancers (Basel. 7(4):2290–2308.
   PubMed Web of Science ®Google Scholar
• Ouyang L, Yan B, Liu Y, Mao C, Wang M, Liu N, Wang Z, Liu S, Shi Y, Chen L, et al. 2020. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor. Signal Transduct Target Ther. 5(1):78.
   PubMed Web of Science ®Google Scholar
• Sanchez-Diaz PC, Chang JC, Moses ES, Dao T, Chen Y, Hung JY. 2017. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma. PLoS One. 12(5):e0176879.
   PubMed Web of Science ®Google Scholar
• Schneider MR, Yarden Y. 2016. The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene. 35(23):2949–2960.
   PubMed Web of Science ®Google Scholar
• Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. 2013. Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev Rep. 9(5):721–730.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. 2017. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 14(10):611–629.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2015. Cancer statistics, 2015. CA Cancer J Clin. 65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Song HM, Lee JE, Kim JH. 2014. Ubiquitin C-terminal hydrolase-L3 regulates EMT process and cancer metastasis in prostate cell lines. Biochem Biophys Res Commun. 452(3):722–727.
   PubMed Web of Science ®Google Scholar
• Swarts DR, Henfling ME, Van Neste L, van Suylen RJ, Dingemans AM, Dinjens WN, Haesevoets A, Rudelius M, Thunnissen E, Volante M, et al. 2013. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res. 19(8):2197–2207.
   PubMed Web of Science ®Google Scholar
• Tanabe S, Quader S, Cabral H, Ono R. 2020. Interplay of EMT and CSC in cancer and the potential therapeutic strategies. Front Pharmacol. 11:904.
   PubMed Web of Science ®Google Scholar
• Tezel E, Hibi K, Nagasaka T, Nakao A. 2000. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res. 6(12):4764–4767.
   PubMed Web of Science ®Google Scholar
• Tomiyasu H, Watanabe M, Sugita K, Goto-Koshino Y, Fujino Y, Ohno K, Sugano S, Tsujimoto H. 2013. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines. Anticancer Res. 33(12):5317–5323.
   PubMed Web of Science ®Google Scholar
• Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, et al. 2009. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 11(12):1487–1495.
   PubMed Web of Science ®Google Scholar
• Yin X, Li YW, Jin JJ, Zhou Y, Ren ZG, Qiu SJ, Zhang BH. 2013. The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma. Oncol Lett. 5(4):1155–1162.
   PubMed Web of Science ®Google Scholar
• Zhang MH, Zhang HH, Du XH, Gao J, Li C, Shi HR, Li SZ. 2020. UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappaB pathway. Oncogene. 39(2):322–333.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hu XW, Yang SJ, Yu Z. 2020. Knockdown of LncRNAZFAS1 suppresses cell proliferation and metastasis in non-small cell lung cancer. Anim Cells Syst (Seoul). 24(2):107–113.
   PubMed Web of Science ®Google Scholar